APO Research
Talk to an analyst

APO RESEARCH · REPORT

Opioid Induced Constipation Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Opioid Induced Constipation Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025197 pages

Choose your research edition.

Industry ResearchOpioid Induced Constipation Drugs Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Opioid Induced Constipation Drugs Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Opioid Induced Constipation Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Opioid Induced Constipation Drugs Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Opioid Induced Constipation Drugs Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Opioid Induced Constipation Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Opioid Induced Constipation Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Opioid Induced Constipation Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Opioid Induced Constipation Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Opioid Induced Constipation Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Opioid Induced Constipation Drugs include Allergan Plc, Bausch Health, C.B. Fleet Company, Cosmo Pharmaceuticals SA, Daewoong Pharmaceutical, Daiichi Sankyo Co Ltd, Ironwood Pharmaceuticals Inc, Mundipharma International Limited and Nektar Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Opioid Induced Constipation Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Opioid Induced Constipation Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Opioid Induced Constipation Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Opioid Induced Constipation Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Opioid Induced Constipation Drugs Segment by Company

Allergan Plc

Bausch Health

C.B. Fleet Company

Cosmo Pharmaceuticals SA

Daewoong Pharmaceutical

Daiichi Sankyo Co Ltd

Ironwood Pharmaceuticals Inc

Mundipharma International Limited

Nektar Therapeutics

Ono Pharmaceutical Co., Ltd

Progenics Pharmaceuticals Inc

Purdue Pharma

S.L.A. Pharma AG

Shionogi & Co., Ltd

Sucampo Pharmaceuticals

Theravance Biopharma Inc

Pfizer

Takeda Pharmaceutical Company Limited

Opioid Induced Constipation Drugs Segment by Type

Lubiprostone

Methyl Naltrexone Bromide

Naldemedine

Alvimopan

Others

Opioid Induced Constipation Drugs Segment by Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Opioid Induced Constipation Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid Induced Constipation Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Opioid Induced Constipation Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid Induced Constipation Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Opioid Induced Constipation Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Opioid Induced Constipation Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Opioid Induced Constipation Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Opioid Induced Constipation Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Opioid Induced Constipation Drugs Industry Trends Table 2. Opioid Induced Constipation Drugs Industry Drivers Table 3. Opioid Induced Constipation Drugs Industry Opportunities and Challenges Table 4. Opioid Induced Constipation Drugs Industry Restraints Table 5. Global Opioid Induced Constipation Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Opioid Induced Constipation Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Opioid Induced Constipation Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Opioid Induced Constipation Drugs Sales Market Share by Manufacturers Table 9. Global Opioid Induced Constipation Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Opioid Induced Constipation Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Opioid Induced Constipation Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Opioid Induced Constipation Drugs Manufacturers, Product Type & Application Table 13. Global Opioid Induced Constipation Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Opioid Induced Constipation Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Lubiprostone Table 17. Major Manufacturers of Methyl Naltrexone Bromide Table 18. Major Manufacturers of Naldemedine Table 19. Major Manufacturers of Alvimopan Table 20. Major Manufacturers of Others Table 21. Global Opioid Induced Constipation Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Opioid Induced Constipation Drugs Sales by Type (2021-2026) & (K Units) Table 23. Global Opioid Induced Constipation Drugs Sales by Type (2027-2032) & (K Units) Table 24. Global Opioid Induced Constipation Drugs Sales Market Share by Type (2021-2026) Table 25. Global Opioid Induced Constipation Drugs Sales Market Share by Type (2027-2032) Table 26. Global Opioid Induced Constipation Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Opioid Induced Constipation Drugs Revenue by Type (2021-2026) & (K Units) Table 28. Global Opioid Induced Constipation Drugs Revenue by Type (2027-2032) & (K Units) Table 29. Global Opioid Induced Constipation Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Opioid Induced Constipation Drugs Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital Pharmacies Table 32. Major Manufacturers of Retail Pharmacies Table 33. Major Manufacturers of Online Pharmacies Table 34. Global Opioid Induced Constipation Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Opioid Induced Constipation Drugs Sales by Application (2021-2026) & (K Units) Table 36. Global Opioid Induced Constipation Drugs Sales by Application (2027-2032) & (K Units) Table 37. Global Opioid Induced Constipation Drugs Sales Market Share by Application (2021-2026) Table 38. Global Opioid Induced Constipation Drugs Sales Market Share by Application (2027-2032) Table 39. Global Opioid Induced Constipation Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Opioid Induced Constipation Drugs Revenue by Application (2021-2026) & (K Units) Table 41. Global Opioid Induced Constipation Drugs Revenue by Application (2027-2032) & (K Units) Table 42. Global Opioid Induced Constipation Drugs Revenue Market Share by Application (2021-2026) Table 43. Global Opioid Induced Constipation Drugs Revenue Market Share by Application (2027-2032) Table 44. Global Opioid Induced Constipation Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Opioid Induced Constipation Drugs Sales by Region (2021-2026) & (K Units) Table 46. Global Opioid Induced Constipation Drugs Sales Market Share by Region (2021-2026) Table 47. Global Opioid Induced Constipation Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Opioid Induced Constipation Drugs Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Opioid Induced Constipation Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Opioid Induced Constipation Drugs Sales by Country (2021-2026) & (K Units) Table 51. North America Opioid Induced Constipation Drugs Sales by Country (2027-2032) & (K Units) Table 52. Europe Opioid Induced Constipation Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Opioid Induced Constipation Drugs Sales by Country (2021-2026) & (K Units) Table 54. Europe Opioid Induced Constipation Drugs Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Opioid Induced Constipation Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Opioid Induced Constipation Drugs Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Opioid Induced Constipation Drugs Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Opioid Induced Constipation Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Opioid Induced Constipation Drugs Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Opioid Induced Constipation Drugs Sales by Country (2027-2032) & (K Units) Table 61. Global Opioid Induced Constipation Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Opioid Induced Constipation Drugs Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Opioid Induced Constipation Drugs Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Opioid Induced Constipation Drugs Revenue Market Share by Region (2021-2026) Table 65. Global Opioid Induced Constipation Drugs Revenue Market Share by Region (2027-2032) Table 66. Allergan Plc Company Information Table 67. Allergan Plc Business Overview Table 68. Allergan Plc Opioid Induced Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Allergan Plc Opioid Induced Constipation Drugs Product Portfolio Table 70. Allergan Plc Recent Development Table 71. Bausch Health Company Information Table 72. Bausch Health Business Overview Table 73. Bausch Health Opioid Induced Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Bausch Health Opioid Induced Constipation Drugs Product Portfolio Table 75. Bausch Health Recent Development Table 76. C.B. Fleet Company Company Information Table 77. C.B. Fleet Company Business Overview Table 78. C.B. Fleet Company Opioid Induced Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. C.B. Fleet Company Opioid Induced Constipation Drugs Product Portfolio Table 80. C.B. Fleet Company Recent Development Table 81. Cosmo Pharmaceuticals SA Company Information Table 82. Cosmo Pharmaceuticals SA Business Overview Table 83. Cosmo Pharmaceuticals SA Opioid Induced Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Cosmo Pharmaceuticals SA Opioid Induced Constipation Drugs Product Portfolio Table 85. Cosmo Pharmaceuticals SA Recent Development Table 86. Daewoong Pharmaceutical Company Information Table 87. Daewoong Pharmaceutical Business Overview Table 88. Daewoong Pharmaceutical Opioid Induced Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Daewoong Pharmaceutical Opioid Induced Constipation Drugs Product Portfolio Table 90. Daewoong Pharmaceutical Recent Development Table 91. Daiichi Sankyo Co Ltd Company Information Table 92. Daiichi Sankyo Co Ltd Business Overview Table 93. Daiichi Sankyo Co Ltd Opioid Induced Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Daiichi Sankyo Co Ltd Opioid Induced Constipation Drugs Product Portfolio Table 95. Daiichi Sankyo Co Ltd Recent Development Table 96. Ironwood Pharmaceuticals Inc Company Information Table 97. Ironwood Pharmaceuticals Inc Business Overview Table 98. Ironwood Pharmaceuticals Inc Opioid Induced Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Ironwood Pharmaceuticals Inc Opioid Induced Constipation Drugs Product Portfolio Table 100. Ironwood Pharmaceuticals Inc Recent Development Table 101. Mundipharma International Limited Company Information Table 102. Mundipharma International Limited Business Overview Table 103. Mundipharma International Limited Opioid Induced Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Mundipharma International Limited Opioid Induced Constipation Drugs Product Portfolio Table 105. Mundipharma International Limited Recent Development Table 106. Nektar Therapeutics Company Information Table 107. Nektar Therapeutics Business Overview Table 108. Nektar Therapeutics Opioid Induced Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Nektar Therapeutics Opioid Induced Constipation Drugs Product Portfolio Table 110. Nektar Therapeutics Recent Development Table 111. Ono Pharmaceutical Co., Ltd Company Information Table 112. Ono Pharmaceutical Co., Ltd Business Overview Table 113. Ono Pharmaceutical Co., Ltd Opioid Induced Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Ono Pharmaceutical Co., Ltd Opioid Induced Constipation Drugs Product Portfolio Table 115. Ono Pharmaceutical Co., Ltd Recent Development Table 116. Progenics Pharmaceuticals Inc Company Information Table 117. Progenics Pharmaceuticals Inc Business Overview Table 118. Progenics Pharmaceuticals Inc Opioid Induced Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Progenics Pharmaceuticals Inc Opioid Induced Constipation Drugs Product Portfolio Table 120. Progenics Pharmaceuticals Inc Recent Development Table 121. Purdue Pharma Company Information Table 122. Purdue Pharma Business Overview Table 123. Purdue Pharma Opioid Induced Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Purdue Pharma Opioid Induced Constipation Drugs Product Portfolio Table 125. Purdue Pharma Recent Development Table 126. S.L.A. Pharma AG Company Information Table 127. S.L.A. Pharma AG Business Overview Table 128. S.L.A. Pharma AG Opioid Induced Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. S.L.A. Pharma AG Opioid Induced Constipation Drugs Product Portfolio Table 130. S.L.A. Pharma AG Recent Development Table 131. Shionogi & Co., Ltd Company Information Table 132. Shionogi & Co., Ltd Business Overview Table 133. Shionogi & Co., Ltd Opioid Induced Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Shionogi & Co., Ltd Opioid Induced Constipation Drugs Product Portfolio Table 135. Shionogi & Co., Ltd Recent Development Table 136. Sucampo Pharmaceuticals Company Information Table 137. Sucampo Pharmaceuticals Business Overview Table 138. Sucampo Pharmaceuticals Opioid Induced Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Sucampo Pharmaceuticals Opioid Induced Constipation Drugs Product Portfolio Table 140. Sucampo Pharmaceuticals Recent Development Table 141. Theravance Biopharma Inc Company Information Table 142. Theravance Biopharma Inc Business Overview Table 143. Theravance Biopharma Inc Opioid Induced Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Theravance Biopharma Inc Opioid Induced Constipation Drugs Product Portfolio Table 145. Theravance Biopharma Inc Recent Development Table 146. Pfizer Company Information Table 147. Pfizer Business Overview Table 148. Pfizer Opioid Induced Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Pfizer Opioid Induced Constipation Drugs Product Portfolio Table 150. Pfizer Recent Development Table 151. Takeda Pharmaceutical Company Limited Company Information Table 152. Takeda Pharmaceutical Company Limited Business Overview Table 153. Takeda Pharmaceutical Company Limited Opioid Induced Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. Takeda Pharmaceutical Company Limited Opioid Induced Constipation Drugs Product Portfolio Table 155. Takeda Pharmaceutical Company Limited Recent Development Table 156. Key Raw Materials Table 157. Raw Materials Key Suppliers Table 158. Opioid Induced Constipation Drugs Distributors List Table 159. Opioid Induced Constipation Drugs Customers List Table 160. Research Programs/Design for This Report Table 161. Authors List of This Report Table 162. Secondary Sources Table 163. Primary Sources List of Figures Figure 1. Opioid Induced Constipation Drugs Product Image Figure 2. Global Opioid Induced Constipation Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Opioid Induced Constipation Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Opioid Induced Constipation Drugs Sales (2021-2032) & (K Units) Figure 5. Global Opioid Induced Constipation Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Opioid Induced Constipation Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Lubiprostone Image Figure 9. Methyl Naltrexone Bromide Image Figure 10. Naldemedine Image Figure 11. Alvimopan Image Figure 12. Others Image Figure 13. Global Opioid Induced Constipation Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Opioid Induced Constipation Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Opioid Induced Constipation Drugs Sales Market Share by Type (2021-2032) Figure 16. Global Opioid Induced Constipation Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Opioid Induced Constipation Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Opioid Induced Constipation Drugs Revenue Market Share by Type (2021-2032) Figure 19. Hospital Pharmacies Image Figure 20. Retail Pharmacies Image Figure 21. Online Pharmacies Image Figure 22. Global Opioid Induced Constipation Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Opioid Induced Constipation Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Opioid Induced Constipation Drugs Sales Market Share by Application (2021-2032) Figure 25. Global Opioid Induced Constipation Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Opioid Induced Constipation Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Opioid Induced Constipation Drugs Revenue Market Share by Application (2021-2032) Figure 28. North America Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Opioid Induced Constipation Drugs Sales Market Share by Country (2021-2032) Figure 30. U.S. Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Opioid Induced Constipation Drugs Sales Market Share by Country (2021-2032) Figure 35. Germany Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Opioid Induced Constipation Drugs Sales Market Share by Country (2021-2032) Figure 42. China Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Opioid Induced Constipation Drugs Sales Market Share by Country (2021-2032) Figure 50. Brazil Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Opioid Induced Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Opioid Induced Constipation Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Opioid Induced Constipation Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Opioid Induced Constipation Drugs Revenue (2021-2032) & (US$ Million) Figure 61. North America Opioid Induced Constipation Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Opioid Induced Constipation Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Europe Opioid Induced Constipation Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Opioid Induced Constipation Drugs Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Opioid Induced Constipation Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Opioid Induced Constipation Drugs Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Opioid Induced Constipation Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Opioid Induced Constipation Drugs Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Opioid Induced Constipation Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Lubiprostone
  • Methyl Naltrexone Bromide
  • Naldemedine
  • Alvimopan
  • Others
Applications
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Companies covered
  • Allergan Plc
  • Bausch Health
  • C.B. Fleet Company
  • Cosmo Pharmaceuticals SA
  • Daewoong Pharmaceutical
  • Daiichi Sankyo Co Ltd
  • Ironwood Pharmaceuticals Inc
  • Mundipharma International Limited
  • Nektar Therapeutics
  • Ono Pharmaceutical Co., Ltd
  • Progenics Pharmaceuticals Inc
  • Purdue Pharma
  • S.L.A. Pharma AG
  • Shionogi & Co., Ltd
  • Sucampo Pharmaceuticals
  • Theravance Biopharma Inc
  • Pfizer
  • Takeda Pharmaceutical Company Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Opioid Induced Constipation Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Opioid Induced Constipation Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Opioid Induced Constipation Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Opioid Induced Constipation Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Opioid Induced Constipation Drugs Market Dynamics
  1. 2.1 Opioid Induced Constipation Drugs Industry Trends
  2. 2.2 Opioid Induced Constipation Drugs Industry Drivers
  3. 2.3 Opioid Induced Constipation Drugs Industry Opportunities and Challenges
  4. 2.4 Opioid Induced Constipation Drugs Industry Restraints
3 Opioid Induced Constipation Drugs Market by Manufacturers
  1. 3.1 Global Opioid Induced Constipation Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Opioid Induced Constipation Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Opioid Induced Constipation Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Opioid Induced Constipation Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Opioid Induced Constipation Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Opioid Induced Constipation Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Opioid Induced Constipation Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Opioid Induced Constipation Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Opioid Induced Constipation Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Opioid Induced Constipation Drugs Tier 1, Tier 2, and Tier 3
4 Opioid Induced Constipation Drugs Market by Type
  1. 4.1 Opioid Induced Constipation Drugs Type Introduction
  2. 4.1.1 Lubiprostone
  3. 4.1.2 Methyl Naltrexone Bromide
  4. 4.1.3 Naldemedine
  5. 4.1.4 Alvimopan
  6. 4.1.5 Others
  7. 4.2 Global Opioid Induced Constipation Drugs Sales by Type
  8. 4.2.1 Global Opioid Induced Constipation Drugs Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Opioid Induced Constipation Drugs Sales by Type (2021-2032)
  10. 4.2.3 Global Opioid Induced Constipation Drugs Sales Market Share by Type (2021-2032)
  11. 4.3 Global Opioid Induced Constipation Drugs Revenue by Type
  12. 4.3.1 Global Opioid Induced Constipation Drugs Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Opioid Induced Constipation Drugs Revenue by Type (2021-2032)
  14. 4.3.3 Global Opioid Induced Constipation Drugs Revenue Market Share by Type (2021-2032)
5 Opioid Induced Constipation Drugs Market by Application
  1. 5.1 Opioid Induced Constipation Drugs Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Online Pharmacies
  5. 5.2 Global Opioid Induced Constipation Drugs Sales by Application
  6. 5.2.1 Global Opioid Induced Constipation Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Opioid Induced Constipation Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Opioid Induced Constipation Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Opioid Induced Constipation Drugs Revenue by Application
  10. 5.3.1 Global Opioid Induced Constipation Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Opioid Induced Constipation Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Opioid Induced Constipation Drugs Revenue Market Share by Application (2021-2032)
6 Global Opioid Induced Constipation Drugs Sales by Region
  1. 6.1 Global Opioid Induced Constipation Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Opioid Induced Constipation Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Opioid Induced Constipation Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Opioid Induced Constipation Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Opioid Induced Constipation Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Opioid Induced Constipation Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Opioid Induced Constipation Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Opioid Induced Constipation Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Opioid Induced Constipation Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Opioid Induced Constipation Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Opioid Induced Constipation Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Opioid Induced Constipation Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Opioid Induced Constipation Drugs Revenue by Region
  1. 7.1 Global Opioid Induced Constipation Drugs Revenue by Region
  2. 7.1.1 Global Opioid Induced Constipation Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Opioid Induced Constipation Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Opioid Induced Constipation Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Opioid Induced Constipation Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Opioid Induced Constipation Drugs Revenue (2021-2032)
  8. 7.2.2 North America Opioid Induced Constipation Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Opioid Induced Constipation Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Opioid Induced Constipation Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Opioid Induced Constipation Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Opioid Induced Constipation Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Opioid Induced Constipation Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Opioid Induced Constipation Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Allergan Plc
  2. 8.1.1 Allergan Plc Company Information
  3. 8.1.2 Allergan Plc Business Overview
  4. 8.1.3 Allergan Plc Opioid Induced Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Allergan Plc Opioid Induced Constipation Drugs Product Portfolio
  6. 8.1.5 Allergan Plc Recent Developments
  7. 8.2 Bausch Health
  8. 8.2.1 Bausch Health Company Information
  9. 8.2.2 Bausch Health Business Overview
  10. 8.2.3 Bausch Health Opioid Induced Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bausch Health Opioid Induced Constipation Drugs Product Portfolio
  12. 8.2.5 Bausch Health Recent Developments
  13. 8.3 C.B. Fleet Company
  14. 8.3.1 C.B. Fleet Company Company Information
  15. 8.3.2 C.B. Fleet Company Business Overview
  16. 8.3.3 C.B. Fleet Company Opioid Induced Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 C.B. Fleet Company Opioid Induced Constipation Drugs Product Portfolio
  18. 8.3.5 C.B. Fleet Company Recent Developments
  19. 8.4 Cosmo Pharmaceuticals SA
  20. 8.4.1 Cosmo Pharmaceuticals SA Company Information
  21. 8.4.2 Cosmo Pharmaceuticals SA Business Overview
  22. 8.4.3 Cosmo Pharmaceuticals SA Opioid Induced Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Cosmo Pharmaceuticals SA Opioid Induced Constipation Drugs Product Portfolio
  24. 8.4.5 Cosmo Pharmaceuticals SA Recent Developments
  25. 8.5 Daewoong Pharmaceutical
  26. 8.5.1 Daewoong Pharmaceutical Company Information
  27. 8.5.2 Daewoong Pharmaceutical Business Overview
  28. 8.5.3 Daewoong Pharmaceutical Opioid Induced Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Daewoong Pharmaceutical Opioid Induced Constipation Drugs Product Portfolio
  30. 8.5.5 Daewoong Pharmaceutical Recent Developments
  31. 8.6 Daiichi Sankyo Co Ltd
  32. 8.6.1 Daiichi Sankyo Co Ltd Company Information
  33. 8.6.2 Daiichi Sankyo Co Ltd Business Overview
  34. 8.6.3 Daiichi Sankyo Co Ltd Opioid Induced Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Daiichi Sankyo Co Ltd Opioid Induced Constipation Drugs Product Portfolio
  36. 8.6.5 Daiichi Sankyo Co Ltd Recent Developments
  37. 8.7 Ironwood Pharmaceuticals Inc
  38. 8.7.1 Ironwood Pharmaceuticals Inc Company Information
  39. 8.7.2 Ironwood Pharmaceuticals Inc Business Overview
  40. 8.7.3 Ironwood Pharmaceuticals Inc Opioid Induced Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Ironwood Pharmaceuticals Inc Opioid Induced Constipation Drugs Product Portfolio
  42. 8.7.5 Ironwood Pharmaceuticals Inc Recent Developments
  43. 8.8 Mundipharma International Limited
  44. 8.8.1 Mundipharma International Limited Company Information
  45. 8.8.2 Mundipharma International Limited Business Overview
  46. 8.8.3 Mundipharma International Limited Opioid Induced Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Mundipharma International Limited Opioid Induced Constipation Drugs Product Portfolio
  48. 8.8.5 Mundipharma International Limited Recent Developments
  49. 8.9 Nektar Therapeutics
  50. 8.9.1 Nektar Therapeutics Company Information
  51. 8.9.2 Nektar Therapeutics Business Overview
  52. 8.9.3 Nektar Therapeutics Opioid Induced Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Nektar Therapeutics Opioid Induced Constipation Drugs Product Portfolio
  54. 8.9.5 Nektar Therapeutics Recent Developments
  55. 8.10 Ono Pharmaceutical Co., Ltd
  56. 8.10.1 Ono Pharmaceutical Co., Ltd Company Information
  57. 8.10.2 Ono Pharmaceutical Co., Ltd Business Overview
  58. 8.10.3 Ono Pharmaceutical Co., Ltd Opioid Induced Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Ono Pharmaceutical Co., Ltd Opioid Induced Constipation Drugs Product Portfolio
  60. 8.10.5 Ono Pharmaceutical Co., Ltd Recent Developments
  61. 8.11 Progenics Pharmaceuticals Inc
  62. 8.11.1 Progenics Pharmaceuticals Inc Company Information
  63. 8.11.2 Progenics Pharmaceuticals Inc Business Overview
  64. 8.11.3 Progenics Pharmaceuticals Inc Opioid Induced Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Progenics Pharmaceuticals Inc Opioid Induced Constipation Drugs Product Portfolio
  66. 8.11.5 Progenics Pharmaceuticals Inc Recent Developments
  67. 8.12 Purdue Pharma
  68. 8.12.1 Purdue Pharma Company Information
  69. 8.12.2 Purdue Pharma Business Overview
  70. 8.12.3 Purdue Pharma Opioid Induced Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Purdue Pharma Opioid Induced Constipation Drugs Product Portfolio
  72. 8.12.5 Purdue Pharma Recent Developments
  73. 8.13 S.L.A. Pharma AG
  74. 8.13.1 S.L.A. Pharma AG Company Information
  75. 8.13.2 S.L.A. Pharma AG Business Overview
  76. 8.13.3 S.L.A. Pharma AG Opioid Induced Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 S.L.A. Pharma AG Opioid Induced Constipation Drugs Product Portfolio
  78. 8.13.5 S.L.A. Pharma AG Recent Developments
  79. 8.14 Shionogi & Co., Ltd
  80. 8.14.1 Shionogi & Co., Ltd Company Information
  81. 8.14.2 Shionogi & Co., Ltd Business Overview
  82. 8.14.3 Shionogi & Co., Ltd Opioid Induced Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Shionogi & Co., Ltd Opioid Induced Constipation Drugs Product Portfolio
  84. 8.14.5 Shionogi & Co., Ltd Recent Developments
  85. 8.15 Sucampo Pharmaceuticals
  86. 8.15.1 Sucampo Pharmaceuticals Company Information
  87. 8.15.2 Sucampo Pharmaceuticals Business Overview
  88. 8.15.3 Sucampo Pharmaceuticals Opioid Induced Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Sucampo Pharmaceuticals Opioid Induced Constipation Drugs Product Portfolio
  90. 8.15.5 Sucampo Pharmaceuticals Recent Developments
  91. 8.16 Theravance Biopharma Inc
  92. 8.16.1 Theravance Biopharma Inc Company Information
  93. 8.16.2 Theravance Biopharma Inc Business Overview
  94. 8.16.3 Theravance Biopharma Inc Opioid Induced Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Theravance Biopharma Inc Opioid Induced Constipation Drugs Product Portfolio
  96. 8.16.5 Theravance Biopharma Inc Recent Developments
  97. 8.17 Pfizer
  98. 8.17.1 Pfizer Company Information
  99. 8.17.2 Pfizer Business Overview
  100. 8.17.3 Pfizer Opioid Induced Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Pfizer Opioid Induced Constipation Drugs Product Portfolio
  102. 8.17.5 Pfizer Recent Developments
  103. 8.18 Takeda Pharmaceutical Company Limited
  104. 8.18.1 Takeda Pharmaceutical Company Limited Company Information
  105. 8.18.2 Takeda Pharmaceutical Company Limited Business Overview
  106. 8.18.3 Takeda Pharmaceutical Company Limited Opioid Induced Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Takeda Pharmaceutical Company Limited Opioid Induced Constipation Drugs Product Portfolio
  108. 8.18.5 Takeda Pharmaceutical Company Limited Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Opioid Induced Constipation Drugs Value Chain Analysis
  2. 9.1.1 Opioid Induced Constipation Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Opioid Induced Constipation Drugs Production Mode & Process
  6. 9.2 Opioid Induced Constipation Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Opioid Induced Constipation Drugs Distributors
  9. 9.2.3 Opioid Induced Constipation Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst